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ABSTRACT 
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths 
in the Western world and interactions between genetic and environmental factors, 
including diet, are suggested to play a critical role in its etiology. Yet, the 
mechanisms by which diet impacts colorectal tumorigenesis remain largely 
unknown. Colorectal cancer evolves as a multistep process, which requires a series 
of genetic and epigenetic alterations in growth regulatory genes. The process is 
accelerated in individuals with inherited cancer predisposition such as Lynch 
syndrome (LS) which is one of the most common inherited cancer susceptibility 
syndromes and caused by inherited mutation in one of the DNA mismatch repair 
(MMR) genes. CRC is thought to develop via the so called adenoma-carcinoma 
sequence. However, the early events that occur in colon mucosa prior to polyp 
formation remain unknown. 
The research presented here investigates the gene expression changes arising in 
histologically normal colonic mucosa as putative cancer-preceding events available 
for early detection. This was achieved by pursuing a long-term feeding experiment 
in the mouse. In the first study, the expression of 94 growth-regulatory genes 
previously linked to human CRC was studied at two time points (5 weeks and 12 
months of age). The test animals were: heterozygote Mlh1+/- (B6.129-Mlh1tm1Rak) 
mice, an animal model for human Lynch syndrome, and the wild type Mlh1+/+ 
littermates, fed with either Western-style (WD) diet containing high amounts of fat 
and reduced levels of fiber, calcium and vitamin D, or healthy AIN-93G control diet. 
Promoter CpG island methylation status was also studied for the genes which 
showed reduced expression. In mice fed for 12 months with WD, proximal colon 
mucosa, the predominant site of cancer formation in LS, exhibited a significant 
expression decrease in tumor suppressor genes, Dkk1, Hoxd1, Slc5a8, and Socs1, 
the latter two only in the Mlh1+/- mice. Furthermore, a reduced mRNA expression 
was accompanied by an increased CpG dinucleotide promoter methylation of the 
respective genes suggesting a cause for the mRNA down regulation. The strongest 
expression decrease together with a significant increase in its promoter 
methylation was seen in Dkk1, an antagonist of the canonical Wnt signaling 
pathway. Furthermore, the inactivation of Dkk1 seemed to predispose to 
neoplasias in the proximal colon, since 4 out of the 6 neoplasms were found in mice 
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which showed Dkk1 inactivation, suggesting that the inactivation of Dkk1 is a 
prominent early marker for colon oncogenesis.  
Since no decrease in Mlh1 expression was seen in the 12-month-old mice in study 
I, our aim was to comprehensively clarify the role of Mlh1 expression during colon 
tumorigenesis, which is usually associated with Lynch syndrome and MSI. Here, the 
same mouse model and diets were used to study cancer-preceding expression 
changes in the colon mucosa of 12 and 18-month-old mice. Due to a longer diet 
experiment (up to 21 mo), more colon carcinomas develop in the mice as compared 
to study I. This enabled us to study the Mlh1 protein expression and MSI status in 
their colon carcinomas, and the effect of inherited predisposition (Mlh1+/) and 
Western-style diet on those.  
Carcinomas developed mainly in WD fed mice. Due to a low number of tumors in 
study I, the diet difference gave no statistically significant difference, yet suggesting 
that WD increases the number and probability of colonic tumors. In study II, at time 
points 12, 18 and 21 mo, 100%, 80% and 72% of CRCs developed in mice which were 
fed with WD, and 0%, 20% and 28% in AIN fed mice, respectively, indicating that 
Western-style diet also accelerates the progression of carcinogenesis.  
CRC development always includes a lack of genomic integrity and the different 
types of genomic instabilities, such as chromosomal instability and MSI are thought 
to reflect distinct cancer initiating mechanisms. Interestingly, in the present study 
neither wildtype Mlh1+/+ nor heterozygote Mlh1+/- mice lacked the Mlh1 protein or 
showed MSI in CRCs, while Mlh1 RNA expression was already significantly 
decreased in their normal mucosa. Instead, CRC mice showed a distinct expression 
profile with shortage of Mlh1 and several other chromosomal segregation gene-
specific transcripts (Bub1, Mis18a, Tpx2, Rad9a, Pms2, Cenpe, Ncapd3, Odf2, and 
Dclre1b) in mucosa and aberrant mitosis in tumors. The genome wide expression 
profiling experiment demonstrated that cancer-preceding changes are already seen 
in histologically normal colon mucosa and a that decreased expression of Mlh1 
together with other chromosomal segregation genes may form a field-defect in 
mucosa and trigger MMR-proficient, chromosomally unstable CRC.  
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INTRODUCTION 
Colorectal cancer is a significant cause of mortality worldwide being the third most 
common cancer and the fourth most common cause of cancer-related deaths 
globally.1 The incidence rate is increasing in the industrialized world.1 High CRC 
incidence is associated with aging, the so called Western lifestyle, and the 
consumption of Western-style diet which is recognized as a major risk factor for 
sporadic CRC.2,3 
CRC evolves as a serial accumulation of genetic and epigenetic alterations during 
aging. Interactions between genetic and environmental factors, such as diet, seem 
to be in key position in its etiology4,5  Yet, the earliest events in normal colon 
mucosa available for early detection and prevention of cancer development remain 
to be elucidated. Although inherited mutations in tumor suppressor genes (TSGs) 
such as APC (adenomatous polyposis coli), an important component of the Wnt/β-
catenin signaling pathway, and MLH1, which controls the mutation rate in a cell5, 
may confer a high lifetime risk of cancer with an early age at onset, colorectal cancer 
is clearly a disease of increasing age.6,7  Accordingly, methylation changes of a small 
subset of TSGs have been detected in the aging colonic mucosa of normal healthy 
individuals, and this methylation involves genes which often become more 
substantially methylated in neoplastic cells8-10, suggesting their role in cancer 
initiation and progression. In addition to aging, some exogenous compounds from 
dietary sources are important modifiers of methylation patterns in the colon.11 This 
probably explains why Western populations consuming considerable amounts of 
red meat, saturated fat and sugar, and only moderate amounts of dietary fiber, 
vitamins and minerals (e.g. calcium, folate, and vitamin D), and plant derived 
nutrients show the highest CRC incidences in the world.4 Epigenetic changes thus 
provide a potential link between nutrition and cancer12 and emphasize the need to 
elucidate dietary effects on gene regulation in intestinal mucosa. 
Cancer development always includes lack of genomic integrity in cells and different 
types of genomic instability, such as chromosomal instability (CIN) and 
microsatellite instability (MIN, MSI), are thought to reflect distinct initiating 
mechanisms in cancer.13 Colon cancer research focuses mainly on tumor 
characteristics, such as genomic instability, which can be utilized in treatment 
design. Recent findings however have revealed that CIN and MSI pathways are not 
mutually exclusive,14-16 suggesting that also tumors with distinct features and 
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instabilities may share initiative genomic aberrations, while different tumor 
characteristics reflect subsequent alterations during cancer development.  
Here, a mouse model is employed to study cancer-preceding expression changes in 
colon mucosa, Mlh1 phenotype in tumors, and the effect of inherited predisposition 
(Mlh1+/-) and Western-style diet on those. A long term feeding experiment was 
conducted with either a healthy rodent diet AIN-93G or Western-style diet modified 
from AIN. WD was used to ensure the development of colon carcinomas, since it 
has previously been shown to cause CRCs in mice even without any predisposing 
mutation or carcinogen treatment.17-20 The mouse model provided a valuable tool 
to study the process of carcinogenesis from the earliest changes in colon mucosa 
until tumor development and characterization. Moreover, the use of an animal 
model enabled the detection of gene expression changes caused by different risk 
factors, such as age, inherited predisposition, and diet, as well as to distinguish 
those that signal carcinogenesis.  
The aim of this thesis was to employ mouse models for LS and sporadic CRC to: 1) 
study the effects of Western-style diet, ageing, and genetic predisposition on gene 
expression in histologically normal mouse colon mucosa; and 2) and of those, to 
identify the expression changes and molecular mechanisms driving the CRC 
development. The obtained results provide new insights to the factors and 
mechanisms involved in CRC development by providing information on how diet, 
genetic predisposition, and aging affect genetic and epigenetic changes in the early 
stages of carcinogenesis. This opens new opportunities for determining the 
epidemiology of the disease, the level of risk, and the treatment of the disease, 
particularly in mutation carriers who already have the inherited predisposition to 
cancer.  
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REVIEW OF LITERATURE 
COLORECTAL CANCER (CRC) 
 
Epidemiology 
 
Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide 
being the third most common cancer and the fourth most common cause of cancer-
related deaths globally and affecting more than 1.2 million new patients annually1. 
CRC is mainly a disease of developed countries and shows large geographic 
differences in the global distribution. The incidence rate varies up to 10 fold across 
the world and highest rates are found in North America, Western Europe, Australia, 
and New Zealand, whereas the lowest are in Africa and Asia21 .  
To date, tumor staging is the most important predictor of clinical outcome for 
patients with colorectal carcinoma. Tumors are graded according to their invasion 
to underlying tissues, lymph node involvement, and presence of distant metastases 
in other organs.22 CRC survival is highly dependent on the stage of disease at 
diagnosis. The 5-year survival rate ranges from 90% in patients showing a localized 
stage tumor, to 70% in patients with regional metastatic cancer, and to 10% for 
patients with distant metastatic cancer23. In high-income countries, overall 5-year 
survival rate (65%) of CRC patients has improved during the past two decades due 
to improvements in cancer treatment and screening. In low-income countries, the 
survival rate is clearly lower, approximately 50%.24,25 CRC mortality can be 
significantly reduced if cancers are diagnosed and cured early.26 Early diagnosis is 
particularly challenging when there is no proper screening methods and practices, 
as is the case in many low-income countries. Screening usually aims to identify high-
risk individuals with pre-cancerous formation.27 Only two screening methods, fecal 
occult blood testing (FOBT) and flexible sigmoidoscopy, have been shown to reduce 
CRC mortality when used in randomized clinical trials.28,29 FOBT has been shown to 
detect most early colorectal cancers and many advanced adenomas, as well as to 
substantially reduce colorectal cancer incidence and mortality30, although it has low 
sensitivity for early polyps28. The method is non-invasive, feasible, widely available, 
and highly acceptable. The combination of annual FOBT with flexible sigmoidoscopy 
every five years28 has been shown to be an especially effective screening method, 
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since the identification of colonic polyps can reduce CRC mortality through earlier 
diagnosis of cancers and the removal of polyps, the precursor lesions of CRC.30 
Incidence rates increase significantly with age, although CRC has recently been 
shown to also be increasing among younger people31,32. CRC risk rises sharply after 
the age of 50 years, although the median age at diagnosis is 70 years.3 The 
significant difference in incidence rates across geographic regions suggests the 
importance of environmental influences on risk to get colon cancer.33 
Epidemiological data shows that high CRC incidence is associated with the so called 
Western lifestyle, characterized by obesity, sedentary lifestyle, smoking, and high 
consumption of red meat and alcohol. Furthermore, inverse association is seen 
between CRC risk and diet rich in vegetables, fiber, dairy, and fish.2,3  
The majority of CRCs are sporadic with no family history or inherited susceptibility 
to CRC. A considerable portion, approximately 30%, of all CRC cases are estimated 
to represent a familial form of the disease with an unusual aggregation of CRC 
among family members who lack a known inherited CRC syndrome.5,34,35 Of all CRC 
cases, 5% are associated with dominantly inherited cancer syndromes caused by 
highly penetrant inherited mutations. The average lifetime risk for sporadic CRC is 
6%. Population studies show a two-fold higher CRC risk in association with family 
history of one affected first-degree relative as compared with those without a 
family history.36 Studies indicate that the risk consists of both hereditary and 
environmental risk factors in familial cancer.37 In hereditary cancer syndromes, the 
cancer risk without any preventive actions may be up to 70-90%38.  
 
CRC development 
 
The pathogenesis of CRC is a very complex and diverse process and influenced by 
multiple factors, some of which are related to genetic predisposition, while others 
are related to diet and lifestyle. To make the picture even more complex, some of 
these aberrations occur prior to the development of any visible histological 
growth.39,40  
The colonic epithelia rapidly renews itself to ensure the proper absorption of 
nutrients from the lumen contents. Stem cells located at the very bottom of the 
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colonic crypts serve as a constant source of new daughter cells which differentiate 
to colonic epithelial cells and migrate towards the epithelial surface where they 
ultimately undergo apoptosis and shed to the lumen.41 There is a fine balance 
between cellular proliferation and apoptosis in colonic epithelia. The disturbed 
homeostasis and increased proliferation rate or reduced apoptosis leads to a clone 
of cells that have escaped normal regulation of growth, proliferation, 
differentiation, and intercellular relationships.   
CRC is thought to develop through an adenoma-carcinoma sequence, which is the 
classical example for stepwise progression of cancer and comprised of multiple 
well-defined histological stages.42 The progressive accumulation of genetic and 
epigenetic alterations that affect genes controlling cell division, apoptosis, and DNA 
repair first gives a growth advantage to abnormal epithelial cells. This eventually 
leads to the formation of the first visible aberration in the mucosa, the aberrant 
crypt focus ACF43 with dysplasia or hyperplasia, followed by benign and advanced 
adenomatous polyps or adenomas, a gland-like growths.44 CRC typically starts from 
focal changes within precancerous polyps that with time grow in size and develop 
more severe dysplasia and develop into in situ carcinoma. Finally, the cells acquire 
the ability to invade the bowel wall and create a metastatic carcinoma.45 While the 
most common genetic aberrations along the adenoma-carcinoma sequence are 
well characterized, the early molecular events which predispose to polyp formation 
and cancer remain unknown.46  
 
MOLECULAR PATHWAYS IN COLON TUMORIGENESIS 
 
Colorectal cancer is a heterogeneous disease its key feature being progressive 
accumulation of mutations and epigenetic alterations which activate oncogenes 
and inactivate tumor suppressor genes that regulate cell growth. According to the 
classical adenoma-carcinoma model47 (Fig. 1) proposed by Fearon and Vogelstein, 
at least four to five different mutated genes are thought to be required for tumor 
development and the type or number of genetic alterations rather than their order 
determines the biological behavior of the tumor.14  
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Figure 1.  Molecular pathways in adenoma-carcinoma model of CRC development. 
Modified from Boland et al 2009.48 
 
 
CRCs may be subdivided by the types of alterations which accumulate during 
carcinogenesis.  Most CRCs show chromosomal instability (CIN) caused by a series 
of deletions, duplications, rearrangements and allelic losses. CIN is associated with 
aneuploidy, the degree of which correlates with the severity of the neoplasia.49 
Other pathways beyond CIN have been discovered: microsatellite instability (MSI, 
MIN) caused by defective DNA mismatch repair (MMR) mechanism, and the CpG 
island methylator phenotype (CIMP) associated with methylation of CpG rich 
regions in gene promoters, which causes silencing of genes.14 Colon tumors show 
often both MSI and CIMP phenotype, since methylation of the MMR gene 
promoters also causes MSI.50 The majority of microsatellite stable (MSS) tumors 
follow the CIN pathway of tumorigenesis.51,52  
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Chromosomal instability 
 
Most CRCs (70-85%) follow the chromosomal instability pathway.15,53  The precise 
cause of chromosomal instability is unknown54, but it has been suggested to be a 
consequence of aberrations in the mitotic checkpoint, centrosome number and 
function, telomere function, DNA damage response, or loss of heterozygosity 
(LOH), which lead to large genomic aberrations.51,55-57 The mitotic checkpoint, also 
known as the spindle assembly checkpoint (SAC), is the major cell cycle control 
mechanism that ensures fidelity of chromosome segregation by delaying the onset 
of anaphase until all pairs of duplicated chromatids are properly aligned on the 
metaphase plate. Defects in checkpoint signaling lead to chromosome 
missegregation and subsequent aneuploidy with abnormal numbers of 
chromosomes being distributed to daughter cells.58  
CIN is associated with mutations in the Adenomatous polyposis coli (APC) and other 
genes that activate the Wnt signaling pathway51. APC mutation is thought to 
happen at a very early stage of tumor development and it is found in 80% of all 
adenomas and carcinomas59,60. A number of other key events associated with the 
development of CIN in CRC have been recognized. These include mutations in 
tumor suppressor genes and oncogenes such as BRAF, TP53, KRAS, CTNNB1, 
PIK3CA, and LOH in chromosome 18q which contains the tumor suppressor genes 
SMAD2, SMAD4, and DCC.51,55-57,61,62 KRAS and BRAF mutations are particularly 
common events in sporadic CRC development. They belong to the intracellular 
RAS/RAF/MEK/mitogen-activated protein kinase (MAPK) cascade, which mediates 
cellular responses to growth signals. KRAS mutations are found in up to 50% of 
carcinomas and advanced adenomas with high grade dysplasia63. A single missense 
mutation of BRAF (BRAF V600E) is found in approximately 10% of CRCs.64 BRAF 
mutations are common in sporadic colorectal cancers (CRCs) with DNA mismatch 
repair (MMR) deficiency caused by promoter methylation of the MMR gene MLH1, 
whereas KRAS mutations are common in MMR proficient CRCs.65 
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Microsatellite instability 
 
Microsatellite instability represents another major pathway to CRC. Approximately 
15% of all CRCs show MSI53. Of these, 20–25% represent hereditary cancer, Lynch 
syndrome (LS), and the rest are sporadic CRCs66 . MSI is caused by MMR deficiency 
and is the hallmark of colorectal cancers in Lynch syndrome67, although the 
phenomenon was initially detected in sporadic tumors68. In sporadic CRC, MSI is 
thought to accelerate rather than initiate tumorigenesis as opposed to Lynch 
syndrome where it is the driving cause.69 
Microsatellites are repetitive DNA sequences including one to six nucleotides. They 
locate often in the non-coding regions of a genome, are repeated up to 100 times, 
and are unique and uniform in length in every tissue of a person. Due to their 
structure, microsatellites are more prone to mutations than the rest of the genome. 
Cells with MSI show a mutator phenotype with a 100 to 1000 fold increase in 
mutation rate when compared to normal cells.70 
MSI is caused by defects in the DNA mismatch repair system. MMR recognizes and 
repairs single nucleotide mismatches and small insertion/deletion loops that arise 
at DNA replication and recombination and escape the proofreading of DNA 
polymerase15. Once both MMR gene alleles have been inactivated, the cell’s 
propensity towards acquiring mutations increases, especially in genes carrying 
microsatellite repeats.71 MMR malfunction is associated with mutational 
inactivation of DNA mismatch repair genes such as mutL homologue 1 (MLH1), mutS 
homologue 2 (MSH2), mutS homologue 6 (MSH6), and postmeiotic segregation 
increased 2 (PMS2) or hypermethylation induced silencing of the MLH1 gene.53,72 
MSI analysis is the primary method to identify tumors suspected to have an 
underlying MMR mutation.66 According to the so-called “Bethesda Guidelines”73, 
five microsatellite markers are used to identify MSI: three dinucleotide and two 
mononucleotide repeat regions. A tumor is classified as MSI-high (MSI-H) when two 
or more markers show new allele size, MSI-low (MSI-L) when one of the five 
markers has new allele size (fragment lengths different from normal tissue), and 
MSI-stable when none of the markers shows shift in the allele size.66  
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CpG island methylator phenotype 
 
The third instability pathway in CRC, the CpG Island Methylator Phenotype (CIMP), is 
seen in approximately 20% of CRCs.14 CIMP is caused by global hypermethylation in 
a subset of colon tumors72. DNA methylation, a covalent modification of genomic 
DNA with methyl groups, modifies gene expression and transmits epigenetic 
information through DNA replication and cell division. The majority of DNA 
methylation is associated with repetitive DNA sequences where it suppresses the 
activity and harmful effects of the sequences incorporated to the genome.74-76 DNA 
methylation also has a role in several normal and important cellular and organismal 
functions such as transcriptional regulation, X-chromosome inactivation, 
imprinting, embryonic development and differentiation, and tissue-specific gene 
expression.77-80 Two different types of aberrant methylation patterns are observed 
in cancer, global hypomethylation which aberrantly activates oncogenes, and 
hypermethylation which inactivates tumor suppressor genes81. CIMP is 
characterized by a genome-wide hypermethylation of CG-rich areas often located 
in gene promoters, the CpG islands (CGIs), resulting in the inactivation of several 
tumor suppressor genes. 7,14,51,82 
A large number of gene promoter CGIs are hypermethylated in the human genome 
during the normal aging process. This type A (aging) methylation is relatively 
common in normal colonic cells as well as in primary CRCs. The cancer specific type  
C (cancer) methylation, on the contrary,  is only seen in colonic tumors, and is 
associated with the CIMP phenotype.72 No standardized gene panel for CIMP exists, 
yet a robust panel of five CIMP marker genes, CACNA1G, IGF2, NEUROG1, RUNX3, 
and SOCS1, have been used to identify CRCs with high level of promoter 
methylation, MSI and BRAFV600E mutation.83 As aberrant methylation happens 
already in the normal appearing mucosa, it serves as a potential marker for 
increased CRC risk.84  
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RISK FACTORS FOR CRC  
 
Age 
 
Colorectal cancer is clearly a disease of increasing age, although during the last 
years CRC has been shown to also be increasing among younger people.31,32 CRC 
risk rises sharply after the age of 50 years, and people between 65 and 85 years are 
six times more likely to develop CRC than people younger than 50.85 The median 
age at diagnosis is 70 years.86,3 Interestingly, older patients present mostly with 
early-stage disease, whereas younger patients, usually in their 40s, carry a more 
aggressive form of the disease.87  
 
The risk of developing CRC increases with advancing age. The risk is caused both by 
an age-related increase in somatic genetic aberrations, such as point mutations, 
single-strand breaks, DNA cross-links, insertions/deletions, oxidative damage, and 
epigenetic aberrations.86,88 Furthermore, different DNA repair pathways such as 
MMR, nucleotide and base excision repair (NER and BER), and double strand brake 
repair (DSB), become less efficient with age leading to further accumulation of 
genetic mutations.89 Along with genetic aberrations aging is also associated with 
accumulation of epigenetic aberrations such as genome-wide hypomethylation and 
gene-specific hypermethylation.90 Growing evidence suggests that epigenetic 
changes might even play a bigger role than the genetic changes in aging and CRC 
development and be a major determinant in the origin of the tumor and tumor 
heterogeneity.91 In fact, over half of the genetic defects that occur in cancer are 
epigenetic alterations as compared to genetic mutations.92 Environmental factors, 
such as diet, are well known to influence gene expression and cancer development 
through epigenetic mechanisms.93 Folate deficiency for example causes altered 
DNA methylation and histone modifications.94 This emphasizes the importance of 
diet-induced accumulation of epigenetic aberrations during aging.90 
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Inherited predisposition 
   
Lynch syndrome 
 
Some individuals appear to be more prone to CRC than others. In fact, a 
considerable proportion, around 30%, of CRCs seem to have a heritable 
component.38,95 Patients with CRC classified as familial have one or more relatives 
diagnosed with CRC, although germline mutations in known cancer susceptibility 
genes are found in only 5–6% of these cases.38   
 
Lynch syndrome (OMIM 120435), previously known as hereditary non-polyposis 
colorectal cancer or HNPCC, is the most common inherited colorectal cancer 
syndrome.96,97 It accounts for approximately 3-5% of all diagnosed CRC cases.98 The 
dominantly inherited syndrome is caused by heterozygote germline mutation in 
one of the DNA mismatch repair genes, most often MLH1 or MSH2 (~90%), and less 
frequently in MSH6 or PMS299. Due to improper DNA mismatch repair, LS carriers 
have significantly increased lifetime risk of developing CRC (50-80%)100 and 
endometrium cancer (40-60%)101 but they may also develop cancers of other organs 
including ovarian, brain, urinary tract, stomach, and pancreas. In Lynch syndrome, 
the age at onset, cancer risk, and tumor spectrum vary depending on which MMR 
gene is mutated.102, 103,104 MLH1 mutation carriers have a higher incidence of CRC 
than MSH2 mutation carriers, which are prone to have more extra-colonic 
manifestations such as the endometrium (lining of the uterus), ovaries, stomach, 
small intestine, liver, gallbladder duct, upper urinary tract, and brain. MSH6 
mutation carriers show a lower incidence of CRC but an excess of endometrial 
cancers as compared to MLH1 and MSH2 mutation carriers. The phenotypic 
consequences of PMS2 mutations are highly variable, often with childhood onset 
of atypical tumors.105  
 
Microsatellite instability in tumors and early age at onset, ~45 years in LS as 
compared to ~65 years in sporadic CRC, are the common hallmarks of Lynch 
syndrome. LS tumors are histologically distinct from sporadic ones. They typically 
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locate at the proximal part of the colon, do not express the protein from the 
mutated MMR gene and exhibit MSI, lymphocytic infiltrate and mucinous histology 
with poor differentiation.106,107 Synchronous and metachronous tumors are 
frequently observed.108 Like sporadic ones, LS tumors also develop from colonic 
polyps, but due to the increased mutation rate, the adenoma-carcinoma sequence 
progresses much more rapidly (2-3 years) as compared with sporadic CRC (6-10 
years). The microsatellite unstable LS tumors have a slightly better prognosis109 and 
five-year survival than sporadic MSS CRC and they respond differently to 
chemotherapy.53 One explanation for the better prognosis in LS compared to 
sporadic CRC is suggested to be the tumor infiltrating lymphocytes in MSI 
carcinomas.110 The clinical phenotypes (age at onset and tumor spectrum) vary 
significantly among mutation carriers and even among the carriers of a similar 
germline mutation, 105,111 suggesting that environmental factors, such as diet, may 
modify the cancer risk even in LS.  
 
In 1991, before the genetic basis for LS was discovered, the International 
Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer established 
Amsterdam I criteria to set guidelines for clinical diagnosis of Lynch syndrome and 
to identify high risk families (Table 1).112 In 1999, the guidelines were further revised 
to Amsterdam II criteria, when some extra-colonic tumors were added as qualifying 
criteria for LS.113 In 1997, revised Bethesda guidelines were published (Table 1).73 
The evaluation of MSI status and/or immunohistochemistry (IHC) of MMR-proteins 
were included in order to better identify individuals who should be genetically 
tested for LS (Table 1).73 The sensitivity and specificity for LS in those meeting any 
one of the guidelines is 82 and 77%, respectively.114   
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Table 1. The international Amsterdam and revised Bethesda guidelines for diagnosis 
of Lynch syndrome99 and tumor MSI status classification  
 
 
 
 
 
 
 
Amsterdam criteria I-II for the diagnosis of Lynch syndrome 
Three or more relatives with histologically verified Lynch syndrome-associated cancer 
(colorectal, endometrial, small bowel, ureter, renal pelvis) 
    One is first degree relative 
    At least two successive affected generations 
    One or more cases diagnosed before age 50 
    FAP excluded 
    Tumors verified by pathological examination 
 
The revised Bethesda guidelines for testing MSI in CRC 
MSI testing of colorectal tumors if: 
    CRC diagnosed before 50 years of age 
    Synchronous/metachronous CRC or other LS-associated tumors detected 
    MSI-H CRC diagnosed in patient under 60 years of age 
    CRC diagnosed in at least one first degree relative before 50 years of age 
    CRC diagnosed in two or more first- or second degree relatives with LS-associated   
    tumors 
Tumor MSI status classification 
    MSI-H when two or more of five markers show new allele size 
    MSI-L when one of five markers show new allele size 
    MSS when none of five markers show new allele size 
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Other hereditary syndromes 
 
The familial cancer-predisposing syndromes of the gastrointestinal tract are 
heterogeneous groups of diseases.115 In addition to Lynch syndrome, the inherited 
CRC syndromes that express adenomatous polyps include familial adenomatous 
polyposis (FAP, OMIM 175100), attenuated FAP (AFAP, OMIM 175100), and 
MUTYH-associated polyposis (MAP, OMIM 608456). The primary lesions in Peutz-
Jeghers syndrome (PJS, OMIM 175200) and juvenile polyposis syndrome (JPS, 
OMIM 174900) are hamartomatous polyps. A hyperplastic polyposis (HPP, OMIM 
610069 and 601228) is a rare condition that has a substantial cancer risk but is 
rarely inherited.101 FAP, attenuated FAP, Peutz-Jeghers syndrome, and juvenile 
polyposis syndrome are inherited in autosomal dominant manner and MAP in 
autosomal recessive manner.  
FAP is the second-most common inherited CRC syndrome with a prevalence of 1 in 
10,000 individuals accounting for less than 1% of all CRCs.116 Characteristic features 
of FAP include the development of hundreds to thousands of colonic adenomas, 
beginning in late childhood / early adolescence, and 100% early onset CRC risk in 
untreated individuals.117 Attenuated FAP is a less-severe form of the disease, 
characterized by an average 69% lifetime risk of CRC.118,119 Both FAP and attenuated 
FAP are caused by germline mutations in tumor suppressor gene APC 
(Adenomatosis Polyposis Coli), which is an important regulator of the Wnt signaling 
pathway.  
MUTYH-associated polyposis (MAP) is caused by mutations of the mutY homolog 
(MUTYH) gene that was firstly described in 2002 in three members of a British 
family.120 It is clinically similar to the AFAP and characterized by early-onset of 
multiple adenomatous polyps of the colon and rectum which have a risk for 
malignant transformation, and infrequent extracolonic manifestations.121  
Peutz-Jeghers syndrome and Juvenile polyposis are characterized by 
hamartomatous polyps that are rare compared to neoplastic and hyperplastic 
polyps and most often found in children.122,123 Juvenile polyposis is a rare syndrome 
(1:100000-160000 live births) characterized by 1-100 hamartomatous polyps 
throughout the gastrointestinal tract, mostly in the colorectal segments, often 
diagnosed in young patients.124 Patients with JPS have a significantly increased life 
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time risk for CRC.125 Peutz-Jeghers syndrome is characterized by mucocutanous 
melanosis, polyposis of the GI-tract, luminal gastrointestinal cancer and 
extraintestinal cancer. The incidence has been estimated to be approximately 
1:8300 and 1:200.000.126 The patients have high risk of cancer in the GI-tract as well 
as extra-intestinal cancer.127     
Hyperplastic polyposis is a rare condition characterized by multiple and/or large 
hyperplastic polyps of the colon whose etiology is unknown.101 Familial cases of HPP 
have been reported, although these are rare.128 The World Health Organization’s 
criteria for HPP include 30 cumulative hyperplastic polyps of any size distributed 
throughout the colon, 5 or more hyperplastic polyps proximal to the sigmoid colon 
with at least 2 being greater than 10 mm in diameter, or at least 1 hyperplastic 
colonic polyp in an individual with a first-degree relative with HPP. Sessile serrated 
polyps/sessile serrated adenomas have also been added to the polyp histologic 
type.129 Patients with HPP have increased CRC risk with a median age at onset of 
50-60 years128 and the carcinomas have a tendency to form in the proximal colon.130 
It is now widely accepted that the serrated neoplasia pathway exists in addition to 
the traditional adenoma–carcinoma sequence. Somatic changes within sessile 
serrated polyps, such as activating BRAF mutations and CIMP phenotype, with or 
without MSI, are important events in the serrated pathway.131   
 
Lifestyle and dietary risks 
 
Colon cancer is a disease of gene expression and only a minority of CRCs appear to 
be related to inherited single high-penetrance gene mutations. Consequently, a 
major determinant of cancer risk appears to be the interaction between genome 
and environment.132 Indeed, the progression from normal colonic epithelium to 
cancer is a complex process involving genetics, epigenetics and environmental 
factors.7 In addition to ageing and heredity, diet is noted to be one of the key 
players in CRC etiology. It is estimated that up to 80% of CRCs may be associated 
with diet.133 Numerous epidemiological studies up to meta-analysis level have been 
conducted to provide evidence for dietary CRC prevention and to improve survival 
among CRC patients. However, the results are often indefinite or even contrary and 
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the molecular mechanisms through which diet affects colon mucosa and CRC 
development still needs to be elucidated.21  
Food components may act directly as mutagens or alter the cellular milieu by 
modulating hormonal axes influencing the growth and proliferation of specific cell 
populations such as colonocytes.132 Dietary factors such as folate, alcohol and 
methionine may be associated with colon cancer by directly influencing the 
expression of key genes such as APC, CDKN2A, MGMT, MLH1, and RASSF1A by 
causing abnormalities in DNA methylation,132,134 synthesis, and repair.80,135   
The wide geographic difference in the global distribution of CRC suggests the 
importance of environmental influences on colorectal carcinogenesis.33 High CRC 
prevalence is associated with the consumption of a Western-style diet 
characterized by high intake of red meat and/or processed meat, high-fat dairy 
products, fast food, refined grains, and sweet foods and drinks.2 Consequently, WD 
containing high amounts of fat, red and processed meat and ethanol from alcoholic 
drinks and low amounts of fiber, calcium, folate and vitamin D, is recognized as a 
major risk factor for sporadic CRC.132,136 On the other hand inverse association is 
seen between CRC risk and diet rich in vegetables, fiber, dairy, and fish.  According 
to the AICR/WCRF Colorectal Cancer Report 2011, physical activity and 
consumption of foods containing dietary fiber, milk, calcium, and vitamin D protects 
against colorectal cancer (Table 2).2,3 
 
Table 2. Lifestyle and dietary factors that affect CRC risk 
Decreases CRC risk Increases CRC risk 
Physical activity Red meat  
Foods containing dietary fiber Processed meat 
Milk Alcoholic drinks 
Calcium Body fatness 
Vitamin D3 Abdominal fatness 
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Western-style diet with decreased levels of nutrients such as  vitamin D and calcium 
has been shown to increase the incidence of pre-neoplastic intestinal lesions and 
malignant neoplasms in various mouse models of intestinal tumorigenesis.137 In 
1999, Lipkin et al. showed that wild-type (wt) mice developed whole colon-crypt 
hyperplasia when fed WD for short periods of time without carcinogen 
administration, suggesting that WD increases the cellular proliferation in colon 
epithelium.137 In 2001 and 2009 they further showed that long term feeding with 
Western-style diet strongly induces both benign and malignant neoplasms in the 
colon of mice without any carcinogen treatment or genetic predisposition.17,18 In a 
mouse feeding study by Lamprecht et al., supplementation of WD with calcium and 
vitamin significantly suppressed the diet-induced changes in wild-type mice and in 
genetically predisposed Apc-mutant mice.138 
The reducing impact of fiber on CRC risk has been shown to be consistent in several 
cohort studies. Especially fiber from cereal, fruits, and grains have been shown to 
reduce the CRC risk.139 Studies have demonstrated that in populations consuming 
high amounts of fat, the concomitant high intake of fibers significantly reduces the 
risk of CRC.140,141 Actually, it has been estimated that CRC risk could be reduced up 
to 30-40% by increasing fiber intake.142,143 Fiber has several effects in the 
gastrointestinal tract, but the precise mechanisms for its protective role remain 
poorly understood. Fiber dilutes fecal content, decreases its transit time, and 
increases stool weight by absorbing liquid, thus diminishing the direct contact time 
of epithelial colonocytes with colon contents. Furthermore, the intestinal 
microflora may be inﬂuenced by ﬁber or may modify the effects of ﬁber in colon 
which in turn may affect the CRC risk.21,140 The gut flora produces fermentation 
products from fiber, especially short-chain fatty acids such as butyrate, which is the 
main source of energy for colonocytes. Short-chain fatty acids also induce 
apoptosis, cell cycle arrest, and differentiation.144  
Calcium and vitamin D have been shown consistently in experimental studies on 
animal models to have anti-cancerous properties, including but not limited to 
stimulating cellular differentiation, reducing proliferation, and inducing apoptosis 
in colonic epithelial cells.33,145 Yet, the results have been inconsistent in 
epidemiologic studies.3 This is probably caused by the fact that the effects of 
vitamin D and calcium are strongly interrelated and, for example, calcium-mediated 
effects are strongly dependent on adequate levels of vitamin D which is needed for 
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its absorption.146 To further clarify the impact of calcium and vitamin D in CRC 
prevention, the molecular mechanisms behind the joint beneficial effects still need 
to be elucidated.  
Along with Western-style diet, alcohol consumption is a well-known and 
established risk factor for colorectal cancer.147-149 The mechanisms by which alcohol 
consumption exerts its carcinogenic effect have not been defined fully, although 
plausible events include: a genotoxic effect of acetaldehyde, the main metabolite 
of ethanol; increased estrogen concentration; a role as solvent for tobacco 
carcinogens; production of reactive oxygen species and nitrogen species; changes 
in folate metabolism; and reduced absorption of other B vitamins (B1, B2, B12) 
which increases vulnerability to oxidative stress.150,151 Alcohol is estimated to 
contribute to 17% and 4% of total CRC burden in men and in women, respectively. 
That is, when consumption exceeds the recommended upper limit of two drinks a 
day for men (about 24 g alcohol), and one for women (about 12 g alcohol).152  
Another major lifestyle factor related to increased CRC risk is tobacco smoking. 
Nicotine from tobacco smoke has been shown to increase cellular proliferation by 
changing the expression of receptors and their phosphorylation patterns in several 
different mitogenic pathways153,154 and to stimulate angiogenesis and 
neovascularization in colon cancer.153,155 In addition to nicotine, tobacco smoke 
contains carcinogenic compounds such as acetaldehyde, benz-pyrenes, aromatic 
amines, and N-nitrosamines that can bind DNA and disrupt normal cell functions.156 
 
Sedentary lifestyle and consumption of energy dense foods high in animal fat and 
protein, refined grains, and added sugar in high-income countries has led to 
exceeding numbers of obese individuals.157,158 Epidemiological evidence clearly 
demonstrates that excess intake of total energy159,160 and consequent obesity, 
defined as a body mass index (BMI) greater than 30 kg/m2, are associated with a 
significantly increased risk (30-70%) of colon cancer, especially in men.161 Excess 
body fat, especially abdominal fat, creates an environment that promotes 
carcinogenesis and discourages apoptosis by directly affecting the levels of 
circulating hormones, such as insulin, insulin like growth factors, and estrogens. It 
also stimulates the body’s inflammatory response, which may contribute to the 
initiation and progression of cancers.3  
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Several studies suggest that physical activity reduces colorectal cancer risk.162-166 
Exercising just one hour per week has been shown to be associated with a lower 
prevalence of colonic polyps and adenomas when compared to people who 
exercised less or not at all167, and at least 30 min of moderate to vigorous daily 
exercise has been shown to protect against CRC.168 Regular physical activity 
elevates basal metabolism and improves tissue oxygenation. This leads to more 
efficient metabolism and finally to reduced body fat, insulin level, and insulin 
resistance which consequently reduces the risk of CRC. Indeed, individuals who take 
regular exercise have 24% smaller CRC risk, regardless of their BMI in comparison 
to people with more sedentary lifestyle.169,170 In contrast, physical inactivity is 
associated with a status of low grade chronic inflammation or latent inflammation, 
and higher estrogen, androgen and insulin levels which are known to promote the 
proliferation of epithelial cells.171 Physical inactivity also increases the 
gastrointestinal transit time of food components and the duration of direct contact 
between food derived carcinogens and the gut epithelium.172 
 
MOUSE MODELS OF COLON CARCINOGENESIS 
 
Today, many genetically engineered mouse strains exist and laboratory mouse (mus 
musculus) has become one of the most used animal models in biomedical research 
thanks to the abundant genetic information and advanced transgene and knock-
out techniques. The mouse models enable the study of molecular mechanisms of 
colorectal carcinogenesis, to test potential preventative and therapeutic strategies, 
and to translate hypotheses derived from cell culture studies into the complex 
physiology of the colon.173 Further advantage to use a mouse as a CRC model is its 
high reproducibility and that as in humans, CRC development seems to follow the 
adenoma-carcinoma sequence174 The shared tumor phenotypes in human and 
genetically-engineered mouse suggest that the basic mechanisms of DNA repair 
and tumor suppression are conserved.175 The short lifespan of mouse models 
allows the long-term study of the effects of various CRC risk factors, such as diet, in 
vivo.173  
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Mouse models of FAP 
 
The first genetically engineered mouse model for human CRC studies is the ApcMin 
mouse (multiple intestinal neoplasia Min), the model counterpart for human 
Familial adenomatous polyposis syndrome176. ApcMin mice spontaneously form a 
number of benign adenomas in the small intestine due to a truncating point 
mutation at position 850 of the Apc gene177. After the ApcMin mouse, many different 
Apc+/- strains have been constructed, e.g. ApcΔ716 and Apc1638N which develop 3-300 
intestinal adenomas depending on the type and location of a mutation and function 
of other modifiers. 178,179,180,181 An important feature of these models is that, unlike 
in human FAP, the majority of intestinal adenomas develop in the small intestine 
instead of colon and the adenomas rarely progress into invasive 
adenocarcinomas.182 
MMR-deficient mouse models 
 
Today, there are several mouse strains with defective MMR capability resembling 
Lynch syndrome. Although heterozygous Msh2, Msh6, and Mlh1 mice fail to 
develop early-onset tumors, homozygous knockout mice are cancer prone and 
develop tumors in multiple organs, including the gastrointestinal tract. These 
mice die prematurely due to aggressive lymphomas resembling patients carrying 
biallelic MMR gene mutations.183  
Msh2+/- mice are unable to repair single base mismatches and small one to four 
base insertion/deletion loops (IDLs), which causes a severe reduction in survival 
and a strong cancer predisposition phenotype.183,184 Homozygous Msh2-/- mice 
usually die in eight months from T-cell lymphomas. They develop adenomas and 
invasive adenocarcinomas, which show high MSI like LS tumors, but develop in 
small intestine.183  
Homozygote Mlh1−/− mice show complete MMR deficiency and usually die after 9-
12 months due to several lymphomas and intestinal carcinomas which show high 
MSI.173,185,186 Also in Mlh1−/− mice the tumors are more often in small intestine than 
in colon.173 Interestingly, when Mlh1 and Msh2 knockout mice are crossed to mice 
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heterozygous for a mutated Apc allele, intestinal tumorigenesis is markedly 
increased.187,188  
Msh6 knock-out mice survive up to 18 months and develop tumors at an older age 
than Msh2- and Mlh1-deficient mice.189 Msh6-/- mice develop lymphomas or 
epithelial tumors originating from the skin, but only rarely from the intestine.190 
Moreover, they often develop endometrial cancers and cancers with variable MSI 
phenotype like human MSH6 mutation carriers191,192  
  
Diet effect modelling in mouse intestine 
 
Murine models provide an excellent starting point in studies on changes mediated 
through diet and for understanding the links between diet, genetics, and colorectal 
cancer.193 Mouse models, especially ApcMin, have been used to assess the effects of 
dietary components on cancer. Several studies have shown that so called Western-
style diet, high in fat and total energy, induces gastrointestinal tumors in mouse 
models for familial intestinal cancer, and even in wild-type mice without any 
carcinogen treatment.17,18,20 This is also seen in the ApcMin mouse were small 
intestinal tumor numbers have been shown to increase 28% and 47% when a total 
fat in basal diet was increased from 3 to 10% and 15%, respectively.194 Results were 
even more drastic in the colon of ApcMin mice where a 207% increase in tumors 
occurred.194 Both the total amount of fat and the type of fat can influence risk in 
genetically predisposed mice. Epidemiological evidence suggests that saturated fat 
increases CRC risk and, inversely, fats from vegetable sources may reduce the 
risk.195 
Some essential nutrients and calorie restriction have been shown to have a 
protective effect against colon cancer. Significantly, feeding a 60% calorie-restricted 
diet resulted in a 60% reduction in small intestinal polyp numbers in ApcMin mice.196 
The effect is probably based on the fact that calorie restriction reduces cell 
proliferation, enhances rate of apoptosis, and reduces inflammation,197 which 
alone or in combination may reduce the CRC risk. Consumption of some fatty acids, 
however, namely steraridonic acid (SDA) and eicosapentaencic acid (EPA), and 
docosahexaenoic acid (DHA) appear to reduce colon cancer risk in ApcMin mice by 
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reducing the number and size of colonic tumors.198 In fact, SDA addition resulted in 
a significant 45% fewer small intestinal tumors and was as effective as the drug 
Sulindac (320 mg/kg) in reducing colonic tumors by 85%.198 The ratio of omega-6 to 
omega-3 fatty acids may be key to determining a response to fatty acids.199 When 
the ratio is low the amount of pro-inflammatory products produced from omega-6 
fatty acids decreases. As a result cell proliferation is depressed and the number of 
visible tumors declines.193  
Some natural compounds, such as sulforaphane a organosulfur compound from 
cruciferous vegetables, chafuroside a flavone derivative from oolong tea, and 
curcumin (diferuloylmethane) from turmeric, have been reported to significantly 
reduce the numbers of intestinal tumors in ApcMin mice.200,201  Sulforaphane 
appears to be an effective anti-cancer agent both in cell culture, and carcinogen-
induced, and genetic cancer models202 due to its ability to induce apoptosis and 
decrease cell proliferation203, reduce inflammation204 and as an antioxidant to 
protect against free radicals.205,206 Curcumin, which acts as an antioxidant and anti-
inflammatory factor through modulation of multiple signaling pathways207 has been 
shown to reduce the incidence of intestinal adenomas ApcMin mice.201 Curcumin has 
several positive pharmacological effects such as anti-inflammatory, antioxidant, 
antimitogenic, anti-cancer, and antiviral properties. Curcumin's anti-inflammatory 
effects are thought to be caused by reducing trans-endothelial monocyte migration 
by reducing mRNA and protein expression of intercellular adhesion molecule-1, 
vascular cell adhesion molecule-1 and P-selectin and by modulating NFκB208, JNK, 
p38, and STAT-3 in endothelial cells.209 Chafuroside has also been reported to cause 
a significant inhibition of intestinal tumors in ApcMin mice.210 Its antitumor 
properties are thought to result from its ability to serve as a free-radical scavenger, 
reduce inflammation, and increase apoptosis.211 
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AIMS OF THE STUDY 
 
Colorectal cancer evolves as a multistep process involving both inherited and 
environment-induced genome aberrations. The main focus of this study was to 
investigate the effects of Western-style diet, ageing, and genetic predisposition on 
gene expression in histologically normal mouse colon mucosa, and of those, to 
identify the expression changes and molecular mechanisms driving the CRC 
development. 
 
Specific aims: 
● To study whether and how WD, ageing, and genetic predisposition (Mlh1 
heterozygosity) induced tumorigenesis (tumor number and stages) in mouse colon 
(I,II) 
● To define the genome-wide gene expression changes caused by WD and genetic 
predisposition in the histologically normal colon mucosa of aging mice (I,II) 
 ● To study whether tumor suppressor gene silencing in histologically normal 
mouse mucosa was caused by their promoter hypermethylation (I) 
● To define the characteristics in transcriptomes, which were associated with 
colorectal oncogenesis (II). 
 
                                                                                                                MATERIALS AND METHODS 
 
35 
 
MATERIALS AND METHODS 
 
MICE, FEEDING STUDY AND DIETS (I,II) 
 
Heterozygote B6.129-Mlh1tm1Rak and wild-type C57BL/6 mice were obtained 
from NCI-MMHCC; National Institutes of Health, Mouse Repository, NCI-Frederick, 
MD. Altogether 12 animals, the Mlh1+/- mice and their wild-type C57BL/6 mates, 
formed six breeder pairs which produced the mouse colony used in the study. Mice 
were genotyped using genomic DNA extracted from earmarks according to the NCI 
– Mouse Repository protocol. Briefly, genotyping primers M001 (TGT CAA TAG GCT 
GCC CTA GG), M002 (TGG AAG GAT TGG AGC TAC GG), and M003 (TTT TCA GTG 
CAG CCT ATG CTC), produce two different length fragments,  separating the normal 
350 bp (M001/M003) and the mutated 500 bp alleles (M001/M002) (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mlh1+/- 
Mutated locus 
Mlh1+/+ 
Wild-type locus 
Figure 2. The structure of mutated and wild-type Mlh1 alleles 
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Figure 3. Experimental design of the feeding studies 
The mice were bred and treated according to the study protocol approved by the 
National Animal Experiment Board in Finland (ESLH-2008-06502/Ym-23). At the 
beginning of the study, five-week old Mlh1+/- and Mlh1+/+ mice were sampled as a 
baseline for the study. The remaining mice from both genotypes were divided into 
two dietary groups and fed ad libitum with either healthy rodent control diet AIN-
93G (AIN) or Western-style diet (WD) modified from AIN (Harlan Teklad) (Table 3). 
WD was designed to resemble, on the nutritional level, the diet consumed in the 
human Western population (high fat and energy content, low amounts of fiber, 
calcium, and vitamin D3). 
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Table 3. Diet nutritional information. 
 AIN93-G WD 
Total energy content (kcal/g) 3.8 4.6 
    Kcal from carbohydrates (%) 63.9 42.3 
    Kcal from protein (%) 18.8 18.5 
    Kcal from fat (%) 17.2 39.2 
Fat source (g/kg)   
    Soybean oil 70 - 
    Anhydrous milkfat - 133 
    Canola oil - 55 
    Sunflower oil - 12 
Vitamin D (IU/kg) 1000 100 
Folic acid (mg/kg) 2 0.2 
Calcium (g/kg) 5 0.5 
Fiber (cellulose) (g/kg) 50 20 
   
 
RNA AND PROTEIN EXPRESSION ANALYSES (I,II) 
 
Sample preparation (I,II) 
 
Mice were sacrificed and sampled at the age of 12, 18, and 21 months (Fig. 3). 
Colons were removed, opened longitudinally, rinsed with 0.9% ice cold sodium 
chloride, and inspected for tumors under a dissecting microscope. Longitudinal 
pieces were collected for normal proximal mucosa. The mucosa was separated from 
the underlying submucosa and musculature under a dissecting microscope. Pieces 
representing approximately one third of the proximal colon were stored in RNAlater 
(Qiagen) at -80°C for RNA extraction and snap frozen in liquid nitrogen for DNA 
extraction. Total RNA was prepared using the RNeasy Plus Kit (Qiagen) with an extra 
DNase treatment (Qiagen) to remove traces of genomic DNA. RNA concentration 
was measured by Nanodrop 1000 (Thermo Fisher Scientific) and Qubit 1.0 (Thermo 
Fisher Scientific) and RNA integrity with the Agilent 2100 Bioanalyzer (Agilent 
technologies). Only high quality RNA (RNA integrity number RIN ≥ 8) qualified for 
expression analysis.  
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All observed colon tumors were collected under a dissecting microscope and 
preserved as FFPE blocks. If a tumor was large enough (three to five mm in 
diameter), approximately half of it was embedded in O.C.T compound (VWR) for 
cryo sampling. Histological investigation, staining and grading of neoplasias was 
carried out at The Finnish Centre for Laboratory Animal Pathology (FCLAP), 
University of Helsinki, Finland. The neoplasias were graded as hyperplasias, 
adenomas and carcinomas according to criteria based on consensus rodent 
intestinal cancer nomenclature.212 The methods used in this study are explained in 
detail in the original publications I and II. A summary of the methods is presented 
in Table 4. 
 
Table 4.  Summary of methods used in the original publications 
Method Publication 
Heterozygote B6.129-Mlh1tm1Rak mice (NCI) and their wild-type 
(Mlh1+/+) littermates 
I, II 
RNA and DNA extractions and quantification I, II 
StellARray gene expression array  I 
TaqMan RT-qPCR I 
Global Pattern Recognition data analysis tool I 
Data-assist v2.0 software  
Transcriptome profiling with RNA-sequencing (single-cell tagged 
reverse transcription, STRT) 
II 
Ingenuity pathway analysis II 
Gene promoter methylation analysis (Sequenom MassARRAY 
EPITYPERTM system) 
I 
FFPE sample cutting I, II 
Immunohistochemistry (IHC) I, II 
Laser capture microdissection (LCM) II 
Microsatellite instability (MSI) analysis II 
Loss of heterozygosity (LOH) analysis II 
Mitosis analysis with feulgen staining II 
Statistical analysis I, II 
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RNA expression analysis of 94 growth regulatory genes (I) 
 
Gene expression array 
 
The RNA expression of histologically normal tissue samples from proximal colonic 
mucosa were analyzed by using a quantitative custom made StellARrayTM platform 
(Lonza Group Ltd, Bar Harbor BioTechnology). The StellARray included 94 genes (73 
TSGs) previously associated with development of colorectal cancer and/or 
documented to exhibit CpG island (CGI) hypermethylation in CRC and other human 
cancers. APC was included in the array as an indicator of ongoing carcinogenesis. 
Each StellARray plate well was loaded with 20 μl of SYBR Green master mix 
containing sample specific cDNA and DNA polymerase (Thermo Scientific). The RT-
qPCR arrays were run on a Mx3000P cycler (Agilent technologies) using the 
following cycling parameters: 50°C for 2 min, 95°C for 7 min, 40 cycles of 95°C for 
15 s, and 60°C for 1 min. The expression differences between different mouse 
groups were analyzed using the Global Pattern Recognition™ (GPR) software (Bar 
Harbor Biotechnology). 
 
TaqMan assay 
 
The results of statistically significant expression changes in StellARray were 
validated by using RT-qPCR and TaqMan gene expression assays. Each sample was 
assayed in triplicate for the target genes, as well as the endogenous reference 
genes using the following cycling parameters: 1 cycle of 95°C for 10 min, 40 cycles 
of 95°C for 15 s, and 60°C for 1 min. Thermal cycling and fluorescence data 
acquisition was performed with a StepOnePlus cycler (Life Technologies) and Cq 
values were called using the Data-assist v2.0 software (Life Technologies). The 
uniformly expressed reference genes were selected using the GeNorm algorithm 
from amongst the 94 genes included in the StellARray.  
If the amount of template was too low to provide reliable results, the RT-qPCR 
validation was performed using pre-amplified cDNA. Samples were multiplex pre-
amplified with TaqMan PreAmp Master Mix Kit (Life Technologies) following 
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manufacturer’s instructions. The cycling parameters were as follows: 1 cycle of 95°C 
for 10 min and 10 pre-amplification cycles of 95°C for 15 s, and 60°C for 4 min. 
 
Genome wide transcriptome analysis (II) 
 
RNA-sequencing 
 
Transcriptome analysis was performed using RNA-sequencing. RNA-seq followed 
the single-cell tagged reverse transcription (STRT) protocol with modifications. 
Briefly, total RNA from 5 week (n=14), 12 mo, and 18 mo (n=40 and 40) mice was 
converted to cDNA and amplified to form an Illumina-compatible library. Four base-
pair unique molecular identifiers were applied and only the absolute number of 
unique reads were included in the subsequent analyses. The samples were 
sequenced on a Illumina HiSeq2000, further processed to fastq files by Casava 1.8.2 
(Illumina), and quality control was performed using the STRTprep pipeline 
(https://github.com/shka/STRTprep). The processed reads were aligned by 
TopHat248 to the mouse RefSeq mm9 reference genome. STRT captures sequences 
at the 5'-end of poly(A)+ RNAs and the aligned reads therefore tend to be 
distributed close to the 5'-end (start site) of genes. Therefore, STRTprep counts only 
the aligned reads at the 5'-untranslated region of protein-coding genes, or within 
the proximal (500 bp) upstream region. 
 
RNA-seq data normalization and data analysis 
 
A read count matrix, with genes as rows and samples as columns was obtained from 
STRTprep pipeline. Different library sizes were normalized using DESeq-style 
normalization213. The data were converted to a more Gaussian like with shifted log 
transformation (???? ? ????? ? ??) and the ComBat program214 was used to filter 
library batch effects. The preprocessing steps were evaluated by looking at the 
hierarchical clustering of samples and by plotting quantiles of expression values for 
each sample.  
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After ComBat normalization the data was no longer integer count values. Therefore, 
three T-test based methods, Voom-Limma, Cyber-T, and Shrinkage-T,215-217 which 
all add a prior to a variance estimate, were considered for analysis of differential 
gene expression. Of these, shrinkage-T is the only method that also allows testing 
with unequal variance between data sets. The three methods were evaluated by 
viewing the separation of cancer samples from the remaining samples in the MDS 
plots with top-k genes, selected using the evaluated statistic. Parameter k was 
varied from 25 to a few hundred. Shrink-T showed the best separation in the 
generated plots across all values of k. Each method’s ability to find correlations with 
Gene Ontology classes was also tested. T-test scores from each method were used 
separately as an input to enrichment analysis tool GSZ (Gene Set Z-score).218 Shrink-
T again generated strongest results. Therefore, only Shrink-T were used in the 
subsequent analyses. 
To see the similarities and differences between the samples, visualizations were 
generated with Multi-dimensional Scaling (MDS). In short, MDS generates a small-
dimensional visualization from the multidimensional data while trying to preserve 
the pairwise distances of samples from the multi-dimensional data. PlotMDS 
distributed in the Limma package was used with some modifications as a basis of 
the analysis.219 The plotMDS was modified in a way that enabled us to use any 
selected score to pick the genes that were used to calculate pair-wise distances. 
The activity of Mlh1 was visualized with ComBat normalized data. Samples were 
grouped based on the sample types (genotype, diet, and time-point) to highlight 
the sample differences.  
 
Protein expression analysis in carcinomas (II) 
 
Formalin-fixed, paraffin-embedded cancer tissue blocks were studied for Mlh1 
expression. The 4 μm thick sections were deparaffinized and rehydrated and heat 
induced antigen retrieval was performed with 10 mM citrate buffer (pH 6). To 
detect Mlh1, the slides were incubated overnight at 4°C with the rabbit monoclonal 
antibody ab92312 (1:1500) (clone EPR3894, Abcam). Stainings were visualized 
using UltraVision Detection System anti-rabbit HRP/DAB (ThermoFisher Scientific).  
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GENE PROMOTER METHYLATION ANALYSIS (I) 
 
For the DNA methylation analysis, only the genes which had shown a significant 
mRNA expression decrease (i.e. candidate hypermethylated TSGs) in association 
with inherited predisposition and/or WD were selected, and the methylation levels 
of their CpG islands (CGIs) were assessed individually for each mouse. Genomic DNA 
for the methylation analysis was extracted using DNeasy Blood & Tissue Kit (Qiagen) 
from colonic tissue samples from the immediate vicinity of those used for RNA 
expression studies. 
The quantitative methylation analysis was performed with MassARRAY EPITYPERTM 
system (Sequenom) which is a bisulphate-based technology relying on base-specific 
cleavage of RNA and matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) to determine the relative extent of methylation in 
DNA fragments containing either one or several subsequent CpG sites, which are 
referred to as CpG units. In the mass spectrum, a distinct signal pattern results from 
the methylated and non-methylated target sequence, and the EPITYPER software 
determines the individual methylation ratios (i.e. signal intensity ratios as 
percentage of methylated to non-methylated signals) for CpG sites/unit within a 
target sequence. The system is able to detect methylation levels as low as 5%. 
The amplicons were primarily selected to cover CGIs annotated by the UCSC 
genome browser and to be overlapping with the transcription start site and the 5’ 
UTR or be in their close proximity. Altogether, twelve different amplicons (lengths 
between 174 and 499 bp) were analyzed, of which eight belonged to the pre-
validated Mouse Standard EpiPanel and four were custom DNA methylation assays 
designed using Sequenom’s EpiDESIGNER software (Sequenom GmbH, 
www.epidesigner.com), for which primer sequences and target sites are provided 
in Table S4 Pussila et al 2013. In order to reduce methylation variability introduced 
during PCR220, three replicate amplifications were performed and pooled for mass 
analysis. The initial methylation data was filtered by Sequenom to exclude poor 
quality measurements. CpG units that yielded data in greater than 75% of the 
samples passed the initial quality control. From these, samples that yielded data in 
greater than 80% for all CpG units within an amplicon were selected for that 
sample/amplicon pair. For further analysis, CpG units which had data available for 
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less than 50% of all samples and samples which had data available for less than 50% 
of all CpG units were excluded.  
 
MICROSATELLITE INSTABILITY STUDY (II) 
 
The microsatellite instability status was analyzed from carcinomas using four 
dinucleotide (D18Mit15, D14Mit15, D10Mit2, and D7Mit91) and two 
mononucleotide (JH104 and U12235) markers. Tumor DNA samples were extracted 
from the cryo-preserved colon carcinomas using laser micro-dissection for cutting 
(Zeiss PALM MicroBeam, Carl Zeiss Microscopy GmbH) and normal DNA control 
samples from the tails of the same mice with QIAamp DNA micro Kit and DNeasy 
Blood & Tissue Kit (Qiagen), respectively. The genomic DNA was amplified with 6-
FAM labeled primers in 11.1X PCR master mix using the following PCR protocol: 1 
min at 96°C, 30 cycles of 20 s at 96°C, 30 s at 62°C, and 15 s at 70°C, and 7 min at 
70°C. The fragments were analyzed with ABI3730xl capillary electrophoresis 
(Thermo Fisher Scientific) and visualized with PeakScanner v1.0 (Thermo Fisher 
Scientific). 
 
LOSS OF Mlh1 HETEROZYGOSITY STUDY (II) 
 
Mlh1 Loss of heterozygosity was analyzed for colon carcinomas using the 
genotyping primers M001, M002, and M003, which produce two different length 
fragments separating the normal and the mutated allele (Fig. 2). DNA was amplified 
with the 11.1X PCR master mix using the following PCR protocol: 1 min at 96°C, 30 
cycles of 20 s at 96°C, 30 s at 62°C, and 15 s at 70°C, and 7 min at 70°C, and the 
fragments were visualized on 1% SB agarose gel. 
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INGENUITY PATHWAY ANALYSIS (II) 
 
Pathway analysis of the top genes which separated the carcinoma mice normal 
mucosa expression patterns from the others was performed using QIAGEN´s 
Ingenuity Pathway Analysis (IPA Software 7.0, Qiagen). The settings for a core 
analysis were as follows: ingenuity knowledge base (genes and endogenous 
chemicals) with both direct and indirect relationships, default network interaction 
settings (include endogenous chemicals, 35 molecules per network and 25 
networks per analysis). Data sources were used with stringent confidence 
(experimentally observed and high predicted) and data obtained in all species was 
selected with a relaxed filter. 
 
ANALYSIS OF MITOTIC ABERRANCES IN CARCINOMAS (II) 
 
Feulgen stain with Midori green background stain was used to visualize nuclear 
material and mitoses in carcinoma samples. The samples were deparaffinized and 
rinsed in 1 M HCl. Mild acid hydrolysis was accomplished by using 60°C 1 M HCl and 
DNA was stained purple in Schiff´s reagent for 45 min. After several bisulfite 
washes, samples were counterstained briefly with 1% Midori light green, 
dehydrated through alcohols to xylene and mount with xylene-based mounting 
media. Stainings were analyzed under light microscope (Zeiss Axio Imager A2, Carl 
Zeiss Microscopy GmbH) and the mitoses in the malignant areas of the carcinoma 
samples were compared to samples from healthy control mice. 
 
STATISTICAL ANALYSES (I,II) 
 
In StellARray RT-qPCR, a common threshold was set across all the plates within the 
experiment. The expression differences between different mouse groups were 
analyzed using the Global Pattern Recognition™ (GPR) software which takes 
advantage of biological replicates to extract significant changes in gene expression. 
GPR executes efficiency correction and reference gene and control group 
normalizations (www.bhbio.com/BHB/dw/products.gpr.html). The StellARray/GPR 
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system does not work with user defined reference genes. Instead, the GPR software 
algorithm determines the best set of stably expressed reference genes within the 
experiment by comparing the expressions of all the genes included in the assay 
between test and control samples. It then generates a global pattern of expression 
changes, and creates a ranked list of significant changes between sample and 
control221. In this way, the selection of reference genes is unbiased since it enables 
the experimental data, and not the researcher, to define the stably expressed 
reference genes. 
In TaqMan RT-qPCR, relative mRNA expression changes were analyzed using the 
comparative Ct (ΔΔCt) method, which presents the data as fold changes in gene 
expression normalized to endogenous reference genes and relative to the control 
group222. Data-assist v2.0 software (Life Technologies) was used for quality control 
and normalization of the quantification cycle (Cq) data, and a median permutation 
method223 was used to determine the significance of the expression fold changes 
compared to the control group with significance level of P < 0.05. 
The correlation between the StellARray expression patterns of 5 week old Mlh1+/+ 
and Mlh1+/- mice was studied using Pearson correlation analysis (R value) of the 
PASW Statistics 18 system. 
Chipster software224 was used to visualize and analyze the methylation data. The 
Non-metric Multi-Dimensional Scaling (NMDS) tool was used to produce two-
dimensional maps based on sample dissimilarity calculated using Euclidean 
distance, and the Dendrogram tool was used to create dendrograms of samples 
using normalized data with Pearson correlation and average linkage method. For 
Chipster analyses, missing methylation values of individual CpG units were defined 
as the median value of the CpG unit within the particular mouse group. 
Comparison of the average methylation levels between different mouse groups was 
performed using Mann-Whitney test of the PASW Statistics 18 system. 
In differential Expression Analysis (DEA) for RNA-seq data modified t-tests Limma, 
cyber-T, and shrinkage t were used. With Limma and cyber-T their own p-value 
estimates were used. Shrinkage-T does not provide a p-value estimate, which were 
estimated by re-calculating Shrinkage-T with 1000 permutations for each gene 
separately. Normal distribution was fitted to the permutations and a one-tailed p-
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value was obtained from the cumulative distribution. Multiple testing correction 
was performed using False Discovery Rate. DEA was mainly used to order the genes 
to most differentially regulated genes. All analysis was performed within the R-
environment. Pathway enrichment analysis was done using IPA which uses Fisher’s 
exact test to analyze over-representation of genes from the analyzed gene groups. 
Here, multiple testing correction was done using the Benjamin-Hochberg method. 
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Figure 4. Number of colon tumors and carcinomas in different diet groups and 
ages in studies I and II 
RESULTS AND DISCUSSION  
 
WESTERN-STYLE DIET AND CRC RISK (I,II) 
 
Colon tumors develop predominantly and earlier in WD fed mice (I, II) 
 
A summary of colonic tumors found in mice is presented in Table 5. The age effect 
was clear in the mouse series since the overall number of tumors increased 
significantly with time (Fig. 4). Heterozygote Mlh1+/- mice showed 67% and 45% of 
all colonic tumors in feeding studies I and II, respectively. Importantly all the 
adenocarcinomas were found in the proximal part of colon and the majority were 
either tubular or mucinous in histology. 
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Table 5 Summary of colon tumors found in studies I and II 
 
Study I Study II   
Time point (mo) 12 12 18 21 
Total number of mice 48 48 48 48 
Tumor incidence (%)* 12.5 10.4 18.8 33.3 
Number of intestinal tumors     
   Carcinomas 1 1 5 7 
   Adenomas 3 3 2 5 
   Hyperplasias 2 1 2 7 
   Total 6 5 9 19 
Tumors in WD mice (%) 80 80 78 64 
Carcinomas in WD mice (%) 100 100 80 72 
Tumors in Mlh1+/- mice (%) 67 40 56 42 
*Number (%) of mice with colon tumor 
 
The significance of WD on CRC risk in studies I and II is highlighted by the fact that 
80% of mice with tumors were fed with WD, and that WD also caused tumor 
development in wild-type mice without inherited predisposition. In 32 mice 
included in study I, two hyperplasias, three adenomas, and one proximal 
adenocarcinoma were found after 12 mo of the feeding study, five out of the six 
tumors found in WD fed mice. The one control diet fed mouse had hyperplasia and 
was a mutation carrier. Due to low number of tumors the diet difference wasn´t 
statistically significant, yet suggesting that WD increases the number and 
probability of colonic tumors. In study II, altogether 33 colonic tumors developed 
during the 21 mo feeding experiment in 144 mice. Here, WD seemed to be a severe 
risk factor for CRC, since approximately 80% of all colon tumors, 10 out of 13 colon 
adenocarcinomas and 14 out of 20 adenomas and hyperplasias, developed in WD 
fed mice (Table 5). In study II, at time points 12, 18, and 21 mo, 100%, 80% and 72% 
of CRCs developed in WD fed mice, respectively, indicating that Western-style diet 
also accelerates the progression of carcinogenesis.  
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These findings follow the observations made by Newmark et al at 200118 that long 
term feeding with Western-style diet strongly induces both benign and malignant 
neoplasms in the colon of laboratory mice without any carcinogen treatment or 
genetic predisposition. The increased number of colon tumors developed in WD-
fed mice is most probably caused by accumulation of cancer promoting genetic and 
epigenetic alterations in the colonic epithelium which precede tumor development. 
The diet used in this study mimics the new Western-style diet 1 (NWD1) used by 
Newmark et al18 with few exceptions. In that study, the main fat source was corn 
oil, while in this study Western-style diet contained high amounts of saturated 
anhydrous milk fat. Although it was assumed that the hard animal fat used in the 
present study would have induced more tumorigenesis as compared to vegetable 
oil, after 18 mo feeding with NWD1 the tumor incidence reach 42% as compared to 
18.8% in this study. The difference may partially be explained by strain differences, 
housing conditions, and the total number of mice in the experiment.   
 
A specific set of tumor suppressor genes (Dkk1, Slc5a8, Hoxd1, and Socs1) show 
significantly altered methylation and mRNA expression in mouse colon mucosa 
(I) 
 
In study I, a candidate gene approach was chosen instead of a genome wide 
expression analysis in order to focus on alterations already shown to be associated 
with human colon cancer. The normal mucosa expression of 94 growth-regulatory 
genes (73 tumor suppressor genes, TSG) previously linked to human CRC was 
studied at two time points (5 wk (week) and 12 mo of age) in the heterozygote 
Mlh1+/- mice and their wild-type littermates. The 5-week-old mice showed a strong 
correlation (Pearson’s R = 0.989, P < 0.01) between the mRNA expression patterns 
at the outset (Fig. 5A). Distinct from the other 93 genes, but in accordance with the 
different genotypes, the expression of Mlh1 was approximately 50% lower in the 
heterozygote mice than in the wt mice (Fig 5B). Overall, the isogenic background in 
the beginning made it justified to reason that expression differences that would 
appear between the different mice groups later were acquired and not the 
outcome of the inherited genetic constitution. 
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Figure 5. (A) The relative expression of Mlh1 in the normal colon mucosa of 5 wk 
old Mlh1+/+ and Mlh1+/- mice and (B) the correlation between relative expression 
patterns of the two genotypes in study I.  
 
 
The expression patterns of 5wk old mice were compared to different 12 mo mouse 
groups (Mlh1+/- AIN, Mlh1+/- WD, Mlh1+/+ AIN, Mlh1+/+ WD). As a result of aging, the 
expression of nine genes was found to be increased or decreased (Table 6) (P < 
0.05). Decreased mRNA levels were seen in Ccnd1 (Cyclin D1), Cdh1 (Cadherin 1), 
and Mal (Myelin and lymphocyte protein, T cell differentiation protein), while 
increased expression was seen in Axin2, Cdx1 (Caudal type homeobox 1), Fzd10 
[Frizzled homolog 10 (Drosophila)], Mbd2 (Methyl-CpG binding domain protein 2), 
Mbd4 (Methyl-CpG binding domain protein 4), and Rasgrf2 (Ras protein-specific 
guanine nucleotide releasing factor 2). Since these changes were found in all mouse 
groups and did not depend on inherited predisposition or WD, they can be 
attributable to aging.  
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Table 6. The genes showing age-related down or up regulation in normal mouse 
colon mucosa (P < 0.05) 
 
Mlh1+/+ AIN Mlh1+/- AIN Mlh1+/+ WD Mlh1+/- WD 
Down regulated genes (fold change, P) 
Ccnd1 3.3 (0.003) 3.8 (0.000) 4.3 (0.001) 3.6 (0.000) 
Cdh1 5.4 (0.002) 4.9 (0.000) 5.9 (0.002) 8.4 (0.000) 
Mal 3.4 (0.025) 3.4 (0.014) 3.2 (0.034) 2.7 (0.028) 
Up regulated genes (fold change, P) 
Axin2 2.6 (0.005) 3.0 (0.002) 1.8 (0.039) 1.6 (0.028) 
Cdx1 4.1 (0.002) 5.6 (0.000) 3.4 (0.002) 5.4 (0.000) 
Fzd10 4.8 (0.002) 7.6 (0.000) 3.4 (0.021) 5.0 (0.000) 
Mbd2 3.3 (0.004) 4.7 (0.000) 3.2 (0.003) 5.7 (0.000) 
Mbd4 3.0 (0.005) 6.0 (0.000) 3.0 (0.004) 3.3 (0.000) 
Rasgrf2 2.3 (0.002) 1.8 (0.006) 2.3 (0.001) 1.5 (0.040) 
 
 
Significant (P < 0.05) expression changes associated with inherited cancer 
predisposition and/or WD were observed in seven genes (Table 7). Decreased 
expression in Dkk1 [Dickkopf homolog 1 (Xenopus laevis)], Slc5a8 [(Solute carrier 
family 5 (iodide transporter), member 8], Hoxd1 (Homeobox D1), and Socs1 
(Suppressor of cytokine signalling 1), and increased expression in Dkk2 [Dickkopf 
homolog 2 (Xenopus laevis)], Rprm (Reprimo, TP53 dependent G2 arrest mediator 
candidate), and Acaa1b (acetyl-Coenzyme A acyltransferase 1B).  
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Table 7. The genes showing up or down regulation in association with inherited 
cancer predisposition and/or Western style diet in normal mouse colon mucosa 
 Mlh1+/+ AIN Mlh1+/+ WD Mlh1+/- AIN Mlh1+/- WD 
Down regulated genes (fold change, P) 
Dkk1 2.0 (0.110) 6.2 (0.003) 5.1 (0.012) 7.3 (0.003) 
Slc5a8 1.3 (0.078) 1.3 (0.224) 1.7 (0.041) 1.5 (0.032) 
Hoxd1 1.1 (0.348) 2.1 (0.019) 2.0 (0.075) 1.5 (0.191) 
Socs1 1.6 (0.460) 1.0 (0.485) 2.7 (0.067) 3.1 (0.026) 
Up regulated genes (fold change, P) 
Dkk2 2.2 (0.108) 1.7 (0.329) 2.2 (0.037) 1.0 (0.637) 
Rprm 1.4 (0.442) 1.1 (0.725) 2.0 (0.017) 3.3 (0.019) 
Acaa1b 2.4 (0.120) 3.5 (0.124) 1.8 (0.140) 9.4 (0.000) 
   Significant expression differences (P < 0.05) marked with red. 
 
Many of the genes showing age-related expression changes in study I associate with 
Wnt/β-catenin signaling. However, their changes did not necessarily imply Wnt 
signaling activation. The lack of colonic carcinomas (n=1) in study I hindered the 
investigation of whether the Wnt/β-catenin signaling pathway was aberrantly 
activated in mouse colon carcinomas as in most human CRCs.225,226 Furthermore, 
no changes were observed in the expression of Ctnnb1, or Apc, a member of the β-
catenin destruction complex in the normal mucosa.227 Yet, the expression of Cdh1 
(cadherin 1, E-cadherin), which is a major component of adherent junctions and 
binds to free cytosolic β-catenin,228 was significantly decreased in all mouse groups, 
downregulation being strongest in the Mlh1+/- WD group.  
The silencing of Wnt antagonist Dkk1 already in histologically normal colon mucosa 
was demonstrated for the first time. The mRNA expression of Dkk1 was completely 
silenced in 16 mice and at least in 10 cases the reason could have been 
hypermethylation. The Dkk1 silencing was associated with carcinogenesis since four 
out of the six colonic neoplasms found in study I developed in mice which showed 
Dkk1 inactivation in normal colon mucosa. Furthermore, the fact that majority of 
the mice not expressing Dkk1 in their colon mucosa were Mlh1 heterozygotes 
(10/16) suggest a link to haploinsufficiency caused by a loss of function mutation in 
Mlh1. On the other hand, the decreased level of vitamin D, which has been shown 
to strongly regulate the human DKK1 expression226,229 may have contributed to the 
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decreased Dkk1 mRNA levels and colonic neoplasias in mice fed with WD. The 
importance of vitamin D in the regulation of Dkk1 by epigenetic modification was 
supported in a recent study where its intake was negatively associated with DKK1 
methylation in a large cohort of CRCs.230 
Hoxd1, which is a target gene for Wnt231 and Polycomb Group (PcG) proteins,232 
provides an illustrative example of dietary effects in study I. This is the first 
demonstration that the expression and methylation of Hoxd1 is altered already in 
histologically normal colonic mucosa and especially in mice fed with WD, suggesting 
that dietary effects may create selective pressure for its silencing. 
Western diet has been reported to induce oxidative stress responses and exert a 
pro-inflammatory stimulus in the colon long before tumors occur.233 Metabolic 
errors may in essence initiate the epigenetic switch that contributes to 
carcinogenesis and cancer progression.234 Changes that were observed in Acaa1b 
and Socs1, for example, may be related to inflammation and alterations in energy 
metabolism. Furthermore, a mild inflammation has been reported to accelerate 
colon carcinogenesis in Mlh1-deficient mice235, a finding in line with the observation 
that most WD-related alterations are linked to Mlh1 heterozygosity (Table 7). 
To compare the methylation levels between 5 wk and 12 mo mice groups the mean 
methylation levels of each CGI for each mouse were calculated. Although the mean 
methylation levels were low in general they were significantly higher among 12 mo 
mice as compared to 5 wk mice, with the exception of Mlh1. This finding was in 
accordance with the observation that all other genes but Mlh1 showed age-related 
decrease in mRNA expression. Overall, mean methylation levels varied between 3% 
and 8% at 5 wk, and between 6% and 15% at 12 mo, respectively. Mean methylation 
was lowest for Mlh1 (5.6%), and highest in Dkk1 (14.7%) and Sfrp1 (14.9%) (Table 
8). 
The average methylation levels were visualized by NMDS plot (non-metric multi-
dimensional scaling) in which the 5wk and 12mo mice segregated into different 
parts of the plots indicating differences in their methylation levels (Fig.6). When 
visualizing the methylation data by dendrogam and histogram, two distinct 
methylation clusters (higher and lower methylation cluster, i.e. Group 1 (G1) and 
Group 2 (G2), respectively) were observed in each CGI. Except for one mouse in 
Sfrp1 and one in Socs1 (B214 and B225, respectively) an identical set of 11 mice 
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clustered into the higher methylation group at CGIs of Dkk1, SLc5a8, Hoxd1, Socs1, 
and Sfrp1. Among those 11 mice, only two belonged to the control Mlh1+/+ AIN 
group (B211, and B214), while the remaining nine mice had either the inherited 
predisposition to CRC (B201, B212, B225, and B232) were fed with WD* (B204, 
B219, B231) or had both risk factors (B215, B220). In addition to these 11 mice 
another 7 mice (B233, B236, B237, B243, B246, B248, and B252) belonged to the 
higher Dkk1 methylation group which showed highest average methylation level at 
12 mo time point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Representative example of higher (G1) and lower (G2) methylation 
clusters. (A) Histogram and (B) MDS plot of Hoxd1 methylation groups G1 (green) 
and G2 (blue). The 5 week old mice marked with red. 
A B 
G1 G2 
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Table 8. Descriptive and comparative statistics of the methylation data for genes, 
Dkk1, Slc5a8, Hoxd1, Socs1, Sfrp1 and Mlh1, for 5wk and 12 mo old mice and for 
higher (G1) and lower (2) methylation cluster, respectively and comparison of the 
mean methylation values between the different mouse groups 
Gene Group 
Mean 
methylation 
(%) 
SD 
5wk vs. 12mo 
 (P) 
G1 vs. G2 
Dkk1 5wk (n =15) 3.4 0.024 0.000 0.000  
12mo (n =32) 14.7 0.075 
 
 
G1 (n =18) 18.7 0.078 
 
 
G2 (n =14) 9.4 0.013 
 
Slc5a8 5wk (n =15) 5.8 0.017 0.000 0.000  
12mo (n =32) 9 0.044 
  
 
G1 (n =11) 14.2 0.037 
  
 
G2 (n =21) 6.3 0.008 
  
Hoxd1 5wk (n =15) 3.7 0.008 0.000 0.000  
12mo (n =32) 9.3 0.032 
  
 
G1 (n =13) 11.9 0.021 
  
 
G2 (n =18) 6.9 0.006 
  
Socs1 5wk (n =15) 8.4 0.012 0.002 0.000  
12mo (n =32) 10.7 0.028 
  
 
G1 (n =10) 14.4 0.021 
  
 
G2 (n =22) 9.1 0.008 
  
Sfrp1 5wk (n =15) 7.1 0.014 0.000 0.000  
12mo (n =32) 14.9 0.040 
  
 
G1 (n =11) 18.9 0.040 
  
 
G2 (n =19) 12.6 0.016 
  
Mlh1 5wk (n =16) 4 0.016 0.089 0.000  
12mo (n =31) 5.6 0.029 
  
 
G1(n =9) 8.6 0.023 
  
 
G2 (n =22) 4.3 0.021 
  
   P (Mann-Whitney test, Exact Sig., 2 tailed) 
 
In study I, a significant age-related increase in CGI methylation levels of Dkk1, Sfrp1, 
Slc5a8, Hoxd1, and Socs1 were observed. Interestingly, Dkk1 as well as Sfrp1 are 
secreted Wnt signaling antagonists236,237 who act as epigenetic gatekeepers. Their 
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aberrant silencing may lock the cells into stem cell like states allowing time for 
genetic gatekeeper mutations in the downstream pathway genes to appear.236-238 
As opposed to other studied genes, Mlh1, which was still well-expressed at 12 
months, did not show significantly increased CGI methylation suggesting that 
expression decreases of the other genes precede the involvement of Mlh1. 
Although MLH1 methylation levels have been reported to increase with age in 
normal human colonic mucosa8,72,84,239,240 the results rather comply with 
studies240,241 classifying Mlh1 as a type C gene, with methylation specificity for 
neoplasia.  
Study I was based on the presumption that, together with aging, certain dietary 
components of the Western style diet are important modifiers of methylation 
patterns in the colon11 and thus may affect the transcription of genes involved in 
tumorigenesis. We reasoned that in mutation carriers requiring just a second hit of 
the inherited susceptibility gene for malignant transformation, it might be possible 
to detect the earliest changes, which might even precede the second hit, and 
distinguish these from alterations occurring later in oncogenesis. These hypotheses 
proved valid when tested on a mouse model for Lynch syndrome. In summary, 
among 73 TSGs, a specific set of genes, and Dkk1 in particular, were identified as 
promising candidates for altered methylation and expression, detectable already in 
histologically normal mucosa and potentiated by an inherited MMR gene mutation 
and Western style diet. Such changes, which are linked to human CRC and occur 
prior to the second hit in the predisposing gene, are associated with WD and may 
be among the very earliest alterations in multistep tumorigenesis. 
Mlh1 seemed to have a surprisingly mild impact on colon tumorigenesis in 12mo 
old mice. Yet, two tumor suppressor genes, Socs1 and Slc5a8, which are known to 
be hypermethylated in human CRC, were significantly down regulated only in the 
Mlh1+/- mice. This suggests a possible impact of Mlh1 heterozygosity on the down-
regulation of the respective genes. The results from study I highlight the interplay 
between genome, epigenome, and environment in colon tumorigenesis and 
encourage studies to explore the potential of the respective genes and alterations 
as biomarkers for diagnostic, prognostic, and therapeutic applications in humans. 
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THE Mlh1 GENE AND CRC RISK (I,II) 
 
The effect of Mlh1 heterozygosity on mouse colon tumorigenesis (I,II)  
 
Since in human Lynch syndrome MLH1 heterozygosity is known predispose to 
colorectal cancer, the effect of Mlh1 heterozygosity on mouse colon tumorigenesis 
was investigated. The tumors were approximately evenly distributed between the 
two genotypes. When the numbers of colonic findings from studies I and II were 
combined, the overall percentage of colonic tumors in Mlh1+/- mice was 49%. The 
distribution of carcinomas, adenomas, and hyperplasias in Mlh1+/- mice were 36% 
(n=5/14), 54% (n=7/13), and 58% (n=7/12), respectively. Mlh1 heterozygosity did 
not increase the number of colonic tumors as such in our study, suggesting that the 
amount of Mlh1 protein in the heterozygote mice is enough to handle the DNA 
mismatch repair function of mouse Mlh1.242 
 
Mouse colon tumors do not lack the Mlh1 protein or show MSI (II) 
 
Due to an increased amount of colon tumors in study II we were able to continue 
to investigate the role of Mlh1 in colon tumorigenesis. The typical Lynch syndrome 
characteristics, MSI status and Mlh1 protein expression53, were analyzed from 
seven carcinomas found in 18 and 21 mo old mice, four in Mlh1+/- mice (E338, E347, 
E437, E444) and three in Mlh1+/+ mice (E402, E410, E421). The inactivation of MLH1 
is a common event both in sporadic and inherited cancers leading to absence of the 
MLH1 protein and MSI.53,243 Surprisingly, all the studied CRCs showed Mlh1 protein 
expression (Fig. 7A), indicating that irrespective of the inherited predisposition in 
the heterozygote mice, the functional allele was still present in the carcinomas. The 
presence of the normal allele was confirmed with LOH study in all the four Mlh1+/- 
carcinomas (Fig. 7B). To study whether the detected Mlh1 protein was functional 
and MMR proficient, the stability of six polymorphic microsatellite regions in the 
mouse genome were analyzed. The markers and their amplified fragment sizes 
were as follows: D14Mit15 (148 bp, 150 bp), D18Mit15 (151 bp, 157 bp), D7Mit91 
(139 bp, 147 bp), D10Mit2 (117 bp, 122 bp), JH104 (178 bp, 181 bp), and U12235 
(79 bp, 83 bp). Altogether six out of the seven CRCs were successfully studied and 
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shown to be microsatellite stable (one sample, E410, could not be amplified), since 
no differences in the fragment lengths were observed between the tumor and 
corresponding normal DNA (study II).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mlh1 mRNA expression is significantly decreased in normal colon mucosa of CRC 
mice (II) 
 
Surprisingly, at the 12 mo time point no expression decrease was seen for Mlh1 in 
normal mouse colon mucosa (Fig. 8, Fig. 9). Yet, at 18 mo time point several mice, 
including the mice with colonic carcinoma, showed extremely low Mlh1 expression 
in their histologically normal mucosa (Fig. 9). In study I the expression was analyzed 
with TaqMan qPCR. In study II a genome wide transcriptome analysis was 
performed from 80 normal colon mucosa samples operated in 12 mo and 18 mo 
old mice. Analysis was performed with RNA sequencing (RNA-seq) using the single-
A B 
Figure 7. Mlh1 protein expression and loss of heterozygosity analyzes. (A) An 
example of a colon carcinoma showing positive Mlh1 expression analyzed by 
immunohistochemistry (mouse E347, serrated adenocarcinoma). (B) Four CRCs 
found in the heterozygote Mlh1+/- mice in study II showing that the normal Mlh1 
allele (350bp) was still present in tumors. 
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cell tagged reverse transcription method (STRT).244,245 The 21 mo old mice were left 
out from the RNAseq study due to many health problems appearing because of 
their old age. Altogether 12,216 expressed transcripts were identified, including 
Mlh1.  Contrary to varying Mlh1 expression levels in general, 5/6 mice (E249, E314, 
E329, E333, E338) who developed carcinoma showed remarkably low Mlh1 
expression in their normal colon mucosa (P=0.03) (Fig. 9). The carcinoma mouse 
E347 had similar Mlh1 expression level as mice with no CRC on average (Fig. 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Relative Mlh1 expression in different 12 mo old mouse groups (Mlh1+/- AIN,
Mlh1+/+ WD, and Mlh1+/- WD) in study I. Expression level is compared to the control 
group (Mlh1+/+ AIN). Each sample is a mixture of eight RNA samples from eight
different mice belonging to each mouse group. Data is presented as mean ± SEM 
(standard error of the mean) (n = 3), *significant difference compared to the control 
group. Median permutation method, P < 0.05. Mlh1 shows the same 50% expression 
difference between the genotypes as at the starting point of the study. AIN, AIN-
93G; WD, Western-style diet 
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Figure 9. The Mlh1 mRNA expression in normal mucosa in study II. The Mlh1 
gene expression levels detected in individual mice at different time points, 
genotypes and diet groups show that five out of six carcinoma mice (red 
triangle) and mice E325 and E332 (black cross) show very low Mlh1 expression. 
ComBat processed shifted-log values from STRT RNA-sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression profiles in colon mucosa form a distinct cluster for CRC mice (II) 
 
Low Mlh1 expression, although a prominent signal, seemed not to be sufficient 
alone to cause colon cancer since several mice without CRC had low Mlh1 
expression as well. In order to identify other genes and pathways involved in CRC 
development the genome-wide expression profiles in the six CRC mice were 
compared with the profiles of 74 12 and 18 mo old mice without CRC.   
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The normal mucosa expression profiles of the six CRC mice were strikingly different 
from the profiles of the other 12 and 18 mo old mice. Altogether 86% of the top 
300 differentially regulated genes in CRC mice were down-regulated in normal 
mucosa and 14% were up-regulated as compared to other 12 and 18 mo old mice. 
Remarkably, the expression profiles of CRC mice formed a clearly distinct cluster 
(Fig. 10) as visualized by an MDS plot created with the 100 most 
altered/differentially regulated genes, indicating a field-defect of clonal 
abnormalities in the epithelial gene expression in normal colon mucosa that 
precede cancer development and predispose to it.246-248  
 
 
 
Figure 10. Genome wide expression profiles of normal colon mucosa in study II. An 
MDS plot created with the 100 most differentially expressed genes between CRC 
(green) mice and mice without cancer (black). The expression profiles of all six mice 
which developed carcinoma up to 18 mo of age form a distinct cluster in the plot. 
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CRC mice show shortage of Mlh1 and chromosomal segregation gene transcripts 
in mucosa and aberrant mitoses in tumors (II) 
 
To further understand the biological functions and pathways enriched among the 
top separating genes in CRC mice, the expression data were analyzed with Ingenuity 
Pathway Analysis (IPA). According to IPA, chromosome segregation (P = 2.92×10-5), 
aneuploidy of fibroblasts (P = 5.64×10-5), checkpoint control (P = 1.10×10-4), DNA 
replication checkpoint (P = 6.66×10-4) and morphology of mitotic spindle (P = 
2.33×10-5) were among the most affected biological pathways. In network analysis, 
the most affected molecular and cellular functions included cell cycle (P = 9.24×10-
5), cellular assembly and organization (P = 9.24×10-5), DNA replication, 
recombination and repair (P = 9.24×10-5), cell death and survival (P = 7.30×10-5), 
cellular growth and proliferation (P = 3.07×10-3), and cellular compromise (P = 
1.79×10-4). The analysis was also repeated with different RNA-seq data 
preprocessing (all mouse samples without ComBat normalization). These results 
confirmed the findings on chromosome segregation (P = 1.03×10-5), aneuploidy of 
fibroblasts (P = 4.57×10-4) and checkpoint control (P = 4.29×10-4).  
The IPA results strongly indicated severe problems in cell cycle regulation and 
mitosis already in normal colon mucosa. In the six mice who developed carcinoma 
up to 18 mo in study II, along with Mlh1, which also triggers checkpoint activation,71 
the most differentially expressed genes that pointed to chromosome segregation 
and spindle assembly checkpoint (SAC) were Bub1 (BUB1, mitotic checkpoint 
serine/threonine kinase), Mis18a (MIS18 kinetochore protein A), Tpx2 (TPX2 
microtubule associated), Rad9a (RAD9 checkpoint clamp component A), Pms2 
(postmeiotic segregation increased 2), Cenpe (centromere protein E), Ncapd3 (non-
SMC condensing II complex subunit D3), Odf2 (outer dens fiber of sperm tails 2), 
and Dclre1b (DNA cross-link repair 1B).  
Five of these 10 genes, Bub1, Mis18a, Tpx2, Rad9a, and Pms2, were strongly down 
regulated in all of the six carcinoma mice (Fig. 11). Mlh1, Cenpe, Ncapd3, Odf2, and 
Dclre1b showed variable levels of down regulation in two CRC mice (E347 and 
E249). In E249, Mlh1 and Dclr1b showed, however, approximately 50% down 
regulation when compared to the average expression level in non-carcinoma mice 
(Fig. 11). In E347, whose carcinoma was histologically different from the others and 
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showed traditional serrated phenotype, Mlh1, Cenpe, Ncapd3, and Odf2 expression 
levels were equal to non-carcinoma mice. Importantly, among all the 74 mice that 
did not develop colon carcinoma up to 12 or 18 mo, only two mice, E325 and E332, 
showed similar low expression of all the 10 genes (Fig. 11). Although, no colonic 
tumors were found in those mice, E325 had bloody feces and anemia, suggesting 
undefined mucosal pathology. 
 
 
Figure 11. The expression levels of 10 chromosomal segregation-specific genes in 
colon mucosa in study II. The expression levels (gene expression values after 
ComBat processing) described as a line chart.  In the carcinoma mice (E249, E314, 
E329, E333, E338, E347), two mice with similar expression profiles with CRC mice 
(E325 and E332) and the average levels of 74 mice without cancer. 
 
Undisturbed mitosis is a central requirement of normal cell cycle and division. In 
cancer cells, mitoses are often aberrant, showing aneuploidy caused by unequal 
segregation of chromosomes and/or structural changes in chromosomes, both of 
which lead to chromosomal instability.249 To validate the RNA sequencing results, 
which suggested impaired cell cycle regulation and mitosis in CRC mice, all the 13 
carcinomas were stained with feulgen and analyzed for mitotic aberrations. 
Although all the carcinomas were well-differentiated early cancers, with limited 
submucosal invasion and relatively lenient cytological changes, they exhibited 
increased mitotic activity and abundant numbers of unbalanced/atypical mitoses in 
contrast to normal tissue samples (Fig. 12). 
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Figure 12. Abnormal mitoses in mouse colon carcinomas in study II. Representative 
pictures of abnormal mitoses (arrows) in (a) serrated adenocarcinoma (mouse 
E347) and (b) tubular adenocarcinoma (mouse E333), and a normal mitosis (arrow 
head).   
 
The MMR mechanism is so essential for normal cell function that it may explain why 
even a small amount of MLH1 appears to be sufficient for MMR function, whereas 
its checkpoint activation role seems to require a full complement of the protein.71 
It has been argued that the MLH1 heterozygosity/haploinsufficiency may drive the 
development of cancer by accumulation of insertion/deletion mutations in other 
gatekeeper genes prior to MSI.250 Indeed, cells with a diminished amount of MLH1 
protein may still be MMR proficient, although they show defects in DNA damage 
signaling.251 Consequently the damaged cells may not activate cell cycle 
checkpoints and enter apoptosis. The observation that low mRNA expression of 
Mlh1 in carcinoma mice was associated with down regulation of several other 
genes related to chromosome segregation and checkpoint control, and consequent 
atypical mitoses in carcinomas supports the proposition that already decreased 
amount of Mlh1, when MMR is still functional, may be associated with aberrant 
chromosome segregation and play an important role in tumorigenesis. 
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CONCLUSIONS 
 
These results on whether and how Western-style diet, ageing and genetic 
predisposition induce tumorigenesis in mouse colon provided the following 
conclusions: 
 
- Western-style diet is a significant risk factor for colon carcinogenesis along 
with aging 
- Cancer-preceding gene expression changes induced by aging, WD, and 
Mlh1+/- already occur in histologically normal mucosa. 
- At least in some of the tumor suppressor genes the down regulation is 
associated with increase in the promoter hypermethylation of the 
respective genes. 
- A decreased expression of Mlh1 together with other chromosomal 
segregation genes may form a field-defect in mucosa and trigger MMR-
proficient, chromosomally unstable CRC. 
- MLH1 mutation carriers develop also microsatellite stable colon cancers. 
- The concomitant down regulation of Mlh1 and several other genes related 
to chromosome segregation and checkpoint control supports the 
proposition that an already decreased amount of Mlh1, when MMR is still 
functional, may have an important role in tumorigenesis 
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FUTURE PROSPECTS 
 
In light of the presented thesis, future prospects for the studies regarding the diet 
experiment may include: 
 
In the presented thesis, several cancer-preceding gene expression changes were 
found already in the normal colon mucosa. However, since the observations were 
made in mice in order to utilize them as cancer predictive biomarkers, the findings 
and the significance of Mlh1 deficiency in chromosomal unstable tumors should be 
further validated in humans. 
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